[go: up one dir, main page]

PE20240220A1 - SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO - Google Patents

SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO

Info

Publication number
PE20240220A1
PE20240220A1 PE2023001454A PE2023001454A PE20240220A1 PE 20240220 A1 PE20240220 A1 PE 20240220A1 PE 2023001454 A PE2023001454 A PE 2023001454A PE 2023001454 A PE2023001454 A PE 2023001454A PE 20240220 A1 PE20240220 A1 PE 20240220A1
Authority
PE
Peru
Prior art keywords
piperidin
difluoro
hydrate
trifluoromethyl
bis
Prior art date
Application number
PE2023001454A
Other languages
English (en)
Inventor
Ki Sook Park
Jung Min Yun
Bong Chan Kim
Kyu Young Kim
Ji Hye Lee
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45995015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20240220(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20240220A1 publication Critical patent/PE20240220A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion se refiere al 1,5 hidrato de tartrato de 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidropirido[3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoro-piperidin-2-ona; caracterizados porque los valores del pico 2 theta en el difractograma de XRD son de 14.7766°, 15.4912°, 17.835°, 20.036°, 21.322° y 22.694°; las absorbancias caracteristicas en el espectro infrarrojo (EI) son 3591, 3401, 3128, 1712, 1655, 1636, 1229, 1205, 1129 y 1058 cm-1; y el espectro de calorimetria de barrido diferencial tiene el pico endotermico de 118.17°C en rangos de temperatura de 90-130 °C y el pico endotermico de 153.44°C en el rango de temperatura de 130-160 °C; un contenido de agua en el rango de 3,5-5,5% y un cambio de peso de 0,8% o menos dependiendo del cambio de humedad externa en el rango de 5 a 95% HR. Este compuesto tiene actividad inhibitoria superior contra la dipeptidil peptidasa-IV (DPP-IV). Tambien se refiere a un proceso para preparar dicho compuesto y una composicion farmaceutica que lo comprende.
PE2023001454A 2010-11-01 2011-10-31 SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO PE20240220A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100107868 2010-11-01
PCT/KR2011/008186 WO2012060590A2 (en) 2010-11-01 2011-10-31 Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate

Publications (1)

Publication Number Publication Date
PE20240220A1 true PE20240220A1 (es) 2024-02-16

Family

ID=45995015

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2013000904A PE20140392A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
PE2018000088A PE20180464A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
PE2023001454A PE20240220A1 (es) 2010-11-01 2011-10-31 SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2013000904A PE20140392A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
PE2018000088A PE20180464A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA

Country Status (29)

Country Link
US (1) US8859567B2 (es)
EP (1) EP2635580B1 (es)
JP (1) JP6193762B2 (es)
KR (1) KR101446789B1 (es)
CN (1) CN103189375B (es)
AP (1) AP3287A (es)
AR (1) AR083591A1 (es)
AU (1) AU2011324253B2 (es)
BR (1) BR112013010586A2 (es)
CA (1) CA2814357C (es)
CL (1) CL2013001137A1 (es)
CO (1) CO6710945A2 (es)
DO (1) DOP2013000090A (es)
EA (1) EA024679B1 (es)
EC (1) ECSP13012599A (es)
GE (1) GEP20156218B (es)
IL (1) IL225808A (es)
MA (1) MA34625B1 (es)
MX (1) MX341584B (es)
MY (1) MY156428A (es)
NZ (1) NZ609644A (es)
PE (3) PE20140392A1 (es)
PH (1) PH12013500685A1 (es)
SG (1) SG189931A1 (es)
TW (1) TWI519533B (es)
UA (1) UA106445C2 (es)
UY (1) UY33696A (es)
WO (1) WO2012060590A2 (es)
ZA (1) ZA201302646B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5066175B2 (ja) 2006-03-31 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MY180726A (en) 2013-03-06 2020-12-08 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
PH12023550900A1 (en) * 2020-10-13 2024-03-04 Lg Chemical Ltd Oral combined formulation including gemigliptin and dapagliflozin and preparation method therefor
KR20250137744A (ko) 2024-03-11 2025-09-19 엠에프씨 주식회사 제미글립틴의 신규 결정형 및 이의 제조방법
KR20250147756A (ko) 2024-03-27 2025-10-14 엠에프씨 주식회사 신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법
KR20250155700A (ko) 2024-04-24 2025-10-31 주식회사 다산제약 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물
CN119285630B (zh) * 2024-09-05 2025-05-27 安徽峆一药业股份有限公司 一种吉格列汀草酸盐及其晶型、制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451369T1 (de) 2002-07-15 2009-12-15 Merck & Co Inc Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
EP1592689A4 (en) * 2003-01-31 2008-12-24 Merck & Co Inc 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
ECSP13012599A (es) 2013-07-31
UY33696A (es) 2012-04-30
CN103189375B (zh) 2016-08-10
MX2013004776A (es) 2013-11-04
CA2814357A1 (en) 2012-05-10
TW201245189A (en) 2012-11-16
AP3287A (en) 2015-05-31
KR101446789B1 (ko) 2014-10-01
NZ609644A (en) 2016-02-26
AR083591A1 (es) 2013-03-06
PH12013500685A1 (en) 2015-10-02
PE20140392A1 (es) 2014-03-22
CL2013001137A1 (es) 2013-09-06
MY156428A (en) 2016-02-26
CN103189375A (zh) 2013-07-03
BR112013010586A2 (pt) 2016-08-09
UA106445C2 (ru) 2014-08-26
EA024679B1 (ru) 2016-10-31
MX341584B (es) 2016-08-25
CO6710945A2 (es) 2013-07-15
GEP20156218B (en) 2015-01-12
MA34625B1 (fr) 2013-10-02
KR20120046069A (ko) 2012-05-09
SG189931A1 (en) 2013-06-28
US8859567B2 (en) 2014-10-14
IL225808A (en) 2016-08-31
AU2011324253A1 (en) 2013-05-02
WO2012060590A3 (en) 2012-06-28
EA201390644A1 (ru) 2014-11-28
US20130203787A1 (en) 2013-08-08
EP2635580A2 (en) 2013-09-11
TWI519533B (zh) 2016-02-01
EP2635580A4 (en) 2014-04-02
CA2814357C (en) 2015-07-07
AU2011324253B2 (en) 2015-10-29
AP2013006866A0 (en) 2013-05-31
ZA201302646B (en) 2014-01-29
JP6193762B2 (ja) 2017-09-06
WO2012060590A2 (en) 2012-05-10
JP2013540810A (ja) 2013-11-07
DOP2013000090A (es) 2018-06-30
PE20180464A1 (es) 2018-03-06
EP2635580B1 (en) 2015-08-12
IL225808A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
PE20240220A1 (es) SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
NI200900081A (es) Peptidommético smac útiles como inhibidores de iap
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX2019011954A (es) Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
PE20150128A1 (es) Moduladores del transporte nuclear y usos de los mismos
MX2016014639A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso para tratar cancer.
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
BR112015025354A2 (pt) compostos di-hidropirido-pirimidínicos como inibidores de autotaxina
MX2018004954A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer.
ECSP088963A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
CO6781480A2 (es) Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1h-inden(2,1-b)piridin-6-carbonitrilo y su uso como inhibidores de hsd 1
WO2014053968A8 (en) Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
MX2009014181A (es) Remedio o preventivo para sindrome de disfuncion de integracion.
ECSP12011718A (es) Utilización de derivados del indol como activadores de nurr-1, para la aplicación en tratamientos de enfermedades como el parkinson
CL2012003553A1 (es) Compuestos derivados de quinolizidina e indolizidina; procedimiento para prepararlos; composicion farmaceutica;y su uso para el tratamiento o profilaxis;de trastornos neurologicos y neurosiquiatricos como psicosis, dolor disfuncion de la memoria y el aprendizaje, deficit de atencion, esquizofrenia y alzheimer.
UA115310C2 (uk) СПІРОЦИКЛІЧНІ СПОЛУКИ НА ОСНОВІ ПОХІДНИХ 2-ОКСІНДОЛУ, ЯКІ МІСТЯТЬ ЯДРО СПІРО[ІНДОЛО-3,1'-ПІРОЛО[3,4-c]ПІРОЛУ] ТА ЗАЛИШКИ БІОГЕННИХ СІРКОВМІСНИХ АМІНОКИСЛОТ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ НА ЇХ ОСНОВІ
TN2013000161A1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
UY30514A1 (es) Compuestos organicos